Anzeige
Mehr »
Mittwoch, 25.06.2025 - Börsentäglich über 12.000 News
TAO +1.800?%, SBAR +85?%, CYK +280?% - jetzt startet KORA auf Unternehmensebene durch!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3D8QG | ISIN: CH1242303498 | Ticker-Symbol: CR5
Stuttgart
25.06.25 | 08:03
16,750 Euro
+0,30 % +0,050
1-Jahres-Chart
OCULIS HOLDING AG Chart 1 Jahr
5-Tage-Chart
OCULIS HOLDING AG 5-Tage-Chart

Aktuelle News zur OCULIS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
09.06.Oculis Holding AG: Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities3
05.06.Oculis Holding AG - S-8, Securities to be offered to employees in employee benefit plans3
OCULIS Aktie jetzt für 0€ handeln
05.06.Oculis Holding AG - 6-K, Report of foreign issuer4
05.06.Leerink Partners raises Oculis stock price target to $50 from $227
05.06.Oculis Holding AG: Oculis Publishes Results of 2025 Annual General Meeting246ZUG, Switzerland, June 05, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) ("Oculis" or the "Company"), today announced the results from its 2025 Annual General Meeting held on...
► Artikel lesen
03.06.Oculis Holding AG: Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities18
09.05.Oculis Holding AG - 6-K, Report of foreign issuer8
08.05.Oculis Holding GAAP EPS of -$0.695
08.05.Oculis Holding AG: Oculis Reports Q1 Financial Results and Provides Company Update185ZUG, Switzerland, May 08, 2025 (GLOBE NEWSWIRE) -- The recent R&D Day (replay) showcased material progress across all three core assets and highlighted potential first-in-class neuroprotection treatment...
► Artikel lesen
25.04.Oculis Holding AG: Oculis Updates Share Capital242ZUG, Switzerland, April 25, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) ("Oculis" or the "Company"), a global biopharmaceutical company, has issued registered ordinary shares...
► Artikel lesen
17.04.Oculis Holding AG: Oculis and EURETINA Announce the 2025 Ramin Tadayoni Award2
15.04.Oculis Holding AG - 6-K, Report of foreign issuer2
15.04.Stifel maintains Buy rating, $35 target on Oculis shares2
15.04.Oculis Holding AG: Oculis Hosts R&D Event Today to Showcase Progress on All Three Pipeline Assets2
10.04.Oculis schließt Patientenrekrutierung für entscheidende DME-Behandlungsstudien ab4
10.04.Oculis completes enrollment for pivotal DME treatment trials2
10.04.Oculis Holding AG: Oculis Completes Enrollment in both DIAMOND Phase 3 Trials of OCS-01 in Diabetic Macular Edema732ZUG, Switzerland, April 10, 2025 (GLOBE NEWSWIRE) -- DIAMOND is the first and only pivotal trial program ever conducted with a topical treatment for diabetic macular edema (DME)Over 800 patients randomized...
► Artikel lesen
09.04.Oculis Holding AG: Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities4
01.04.Oculis Holding AG: Oculis to Host In-Person and Virtual R&D Day on Key Business Updates and the Development Plans for Privosegtor (OCS-05) in Acute Optic Neuritis and Beyond6
20.03.Oculis Holding AG: Oculis Publishes Notifications of Transactions by Person Discharging Managerial Responsibilities2
Weiter >>
46 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1